A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
Roxadustat is the world's first small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor. Its adverse effect of causing hypothyroidism with low thyroid-stimulating hormone (TSH) is relatively rare and manifests subtly in elderly patients with multiple coexisting diseases. This artic...
Saved in:
| Main Authors: | YAN Xuelian, TANG Bingying, QU Xuan, ZHANG Ning, KANG Lin |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2025-03-01
|
| Series: | Xiehe Yixue Zazhi |
| Subjects: | |
| Online Access: | https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01) -
Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01) -
Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
by: Serina Kita, et al.
Published: (2024-09-01) -
Roxadustat in CKD and transplant patients: A new era in anemia management
by: Muhammad Tassaduq Khan, et al.
Published: (2025-03-01) -
Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats
by: Zhaoli Gao, et al.
Published: (2025-03-01)